Oxaliplatin-Fluoropyrimidine Combination (XELOX) Therapy Does Not Affect Plasma Amino Acid Levels and Plasma Markers of Oxidative Stress in Colorectal Cancer Surgery Patients: A Pilot Study

Roberto Aquilani, Silvia Brugnatelli, Maurizia Dossena, Roberto Maestri, Sara Delfanti, Daniela Buonocore, Federica Boschi, Elena Simeti, Anna Maria Condino, Manuela Verri

Research output: Contribution to journalArticle

Abstract

Chemotherapy for colorectal cancer may lower muscle protein synthesis and increase oxidative stress. We hypothesize that chemotherapy may worsen plasma amino acids (AAs) and markers of oxidative stress (MOS). Therefore, this study aimed to document plasma AAs and MOS before, during and after chemotherapy in colorectal cancer (CRC) surgery patients. Fourteen normal-weight CRC patients were enrolled one month after surgery and scheduled for oxaliplatin-fluoropyrimidine combination (XELOX) therapy. Venous blood samples for AA and MOS (malondialdehyde, MDA; 8-hydroxy-2'-deoxyguanosine, 8-OHdG) measurements were drawn in fasting patients before each oxaliplatin infusion at initiation (A), 1 month (B) and 3 months (C) of the therapy, and after XELOX had finished (6 months, D). The results showed that during XELOX therapy (from phase B to phase D), in comparison to baseline (phase A), the branched chain amino acid/essential amino acid ratio, branched chain amino acids expressed as a percentage of total AAs, and arginine expressed as a percentage of total AAs significantly decreased (p = 0.017, p = 0.028, p = 0.028, respectively). Plasma levels of MOS did not change significantly. This study indicates that XELOX therapy does not affect plasma AA levels or worsen oxidative stress.

Original languageEnglish
JournalNutrients
Volume11
Issue number11
DOIs
Publication statusPublished - Nov 5 2019

Fingerprint

oxaliplatin
Colorectal Surgery
colorectal neoplasms
Colorectal Neoplasms
Oxidative Stress
oxidative stress
surgery
Amino Acids
therapeutics
amino acids
drug therapy
Branched Chain Amino Acids
branched chain amino acids
Drug Therapy
Therapeutics
Essential Amino Acids
Muscle Proteins
muscle protein
Malondialdehyde
essential amino acids

Keywords

  • chemotherapy
  • colorectal cancer
  • oxidative stress
  • plasma amino acids
  • surgery

ASJC Scopus subject areas

  • Food Science
  • Nutrition and Dietetics

Cite this

Oxaliplatin-Fluoropyrimidine Combination (XELOX) Therapy Does Not Affect Plasma Amino Acid Levels and Plasma Markers of Oxidative Stress in Colorectal Cancer Surgery Patients : A Pilot Study. / Aquilani, Roberto; Brugnatelli, Silvia; Dossena, Maurizia; Maestri, Roberto; Delfanti, Sara; Buonocore, Daniela; Boschi, Federica; Simeti, Elena; Condino, Anna Maria; Verri, Manuela.

In: Nutrients, Vol. 11, No. 11, 05.11.2019.

Research output: Contribution to journalArticle

@article{5a9a714c2ac04fc4b4ce91928b858496,
title = "Oxaliplatin-Fluoropyrimidine Combination (XELOX) Therapy Does Not Affect Plasma Amino Acid Levels and Plasma Markers of Oxidative Stress in Colorectal Cancer Surgery Patients: A Pilot Study",
abstract = "Chemotherapy for colorectal cancer may lower muscle protein synthesis and increase oxidative stress. We hypothesize that chemotherapy may worsen plasma amino acids (AAs) and markers of oxidative stress (MOS). Therefore, this study aimed to document plasma AAs and MOS before, during and after chemotherapy in colorectal cancer (CRC) surgery patients. Fourteen normal-weight CRC patients were enrolled one month after surgery and scheduled for oxaliplatin-fluoropyrimidine combination (XELOX) therapy. Venous blood samples for AA and MOS (malondialdehyde, MDA; 8-hydroxy-2'-deoxyguanosine, 8-OHdG) measurements were drawn in fasting patients before each oxaliplatin infusion at initiation (A), 1 month (B) and 3 months (C) of the therapy, and after XELOX had finished (6 months, D). The results showed that during XELOX therapy (from phase B to phase D), in comparison to baseline (phase A), the branched chain amino acid/essential amino acid ratio, branched chain amino acids expressed as a percentage of total AAs, and arginine expressed as a percentage of total AAs significantly decreased (p = 0.017, p = 0.028, p = 0.028, respectively). Plasma levels of MOS did not change significantly. This study indicates that XELOX therapy does not affect plasma AA levels or worsen oxidative stress.",
keywords = "chemotherapy, colorectal cancer, oxidative stress, plasma amino acids, surgery",
author = "Roberto Aquilani and Silvia Brugnatelli and Maurizia Dossena and Roberto Maestri and Sara Delfanti and Daniela Buonocore and Federica Boschi and Elena Simeti and Condino, {Anna Maria} and Manuela Verri",
year = "2019",
month = "11",
day = "5",
doi = "10.3390/nu11112667",
language = "English",
volume = "11",
journal = "Nutrients",
issn = "2072-6643",
publisher = "NLM (Medline)",
number = "11",

}

TY - JOUR

T1 - Oxaliplatin-Fluoropyrimidine Combination (XELOX) Therapy Does Not Affect Plasma Amino Acid Levels and Plasma Markers of Oxidative Stress in Colorectal Cancer Surgery Patients

T2 - A Pilot Study

AU - Aquilani, Roberto

AU - Brugnatelli, Silvia

AU - Dossena, Maurizia

AU - Maestri, Roberto

AU - Delfanti, Sara

AU - Buonocore, Daniela

AU - Boschi, Federica

AU - Simeti, Elena

AU - Condino, Anna Maria

AU - Verri, Manuela

PY - 2019/11/5

Y1 - 2019/11/5

N2 - Chemotherapy for colorectal cancer may lower muscle protein synthesis and increase oxidative stress. We hypothesize that chemotherapy may worsen plasma amino acids (AAs) and markers of oxidative stress (MOS). Therefore, this study aimed to document plasma AAs and MOS before, during and after chemotherapy in colorectal cancer (CRC) surgery patients. Fourteen normal-weight CRC patients were enrolled one month after surgery and scheduled for oxaliplatin-fluoropyrimidine combination (XELOX) therapy. Venous blood samples for AA and MOS (malondialdehyde, MDA; 8-hydroxy-2'-deoxyguanosine, 8-OHdG) measurements were drawn in fasting patients before each oxaliplatin infusion at initiation (A), 1 month (B) and 3 months (C) of the therapy, and after XELOX had finished (6 months, D). The results showed that during XELOX therapy (from phase B to phase D), in comparison to baseline (phase A), the branched chain amino acid/essential amino acid ratio, branched chain amino acids expressed as a percentage of total AAs, and arginine expressed as a percentage of total AAs significantly decreased (p = 0.017, p = 0.028, p = 0.028, respectively). Plasma levels of MOS did not change significantly. This study indicates that XELOX therapy does not affect plasma AA levels or worsen oxidative stress.

AB - Chemotherapy for colorectal cancer may lower muscle protein synthesis and increase oxidative stress. We hypothesize that chemotherapy may worsen plasma amino acids (AAs) and markers of oxidative stress (MOS). Therefore, this study aimed to document plasma AAs and MOS before, during and after chemotherapy in colorectal cancer (CRC) surgery patients. Fourteen normal-weight CRC patients were enrolled one month after surgery and scheduled for oxaliplatin-fluoropyrimidine combination (XELOX) therapy. Venous blood samples for AA and MOS (malondialdehyde, MDA; 8-hydroxy-2'-deoxyguanosine, 8-OHdG) measurements were drawn in fasting patients before each oxaliplatin infusion at initiation (A), 1 month (B) and 3 months (C) of the therapy, and after XELOX had finished (6 months, D). The results showed that during XELOX therapy (from phase B to phase D), in comparison to baseline (phase A), the branched chain amino acid/essential amino acid ratio, branched chain amino acids expressed as a percentage of total AAs, and arginine expressed as a percentage of total AAs significantly decreased (p = 0.017, p = 0.028, p = 0.028, respectively). Plasma levels of MOS did not change significantly. This study indicates that XELOX therapy does not affect plasma AA levels or worsen oxidative stress.

KW - chemotherapy

KW - colorectal cancer

KW - oxidative stress

KW - plasma amino acids

KW - surgery

UR - http://www.scopus.com/inward/record.url?scp=85074624491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074624491&partnerID=8YFLogxK

U2 - 10.3390/nu11112667

DO - 10.3390/nu11112667

M3 - Article

C2 - 31694176

AN - SCOPUS:85074624491

VL - 11

JO - Nutrients

JF - Nutrients

SN - 2072-6643

IS - 11

ER -